The Evolving Role of Maintenance Therapy Using Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) in the Management of Advanced Non-Small-Cell Lung Cancer
The epidermal growth factor receptor (EGFR) plays an important role in the development of many cancers, including non-small cell lung cancer. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are a class of novel biologically-targeted agents widely used in the management of rec...
Saved in:
| Published in: | Clinical Medicine Insights. Oncology Vol. 2012; no. 6; pp. 137 - 147 |
|---|---|
| Main Authors: | , |
| Format: | Journal Article |
| Language: | English |
| Published: |
London, England
Libertas Academica
01.01.2012
SAGE Publishing SAGE Publications Sage Publications Ltd. (UK) Sage Publications Ltd |
| Subjects: | |
| ISSN: | 1179-5549, 1179-5549 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | The epidermal growth factor receptor (EGFR) plays an important role in the development of many cancers, including non-small cell lung cancer. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are a class of novel biologically-targeted agents widely used in the management of recurrent non-small cell lung cancer. Erlotinib, one of the EGFR TKIs, is currently FDA approved in second and third line therapy. However, recent studies showed that erlotinib is also effective as maintenance therapy after initial chemotherapy, improving disease free survival and possibly overall survival. Our current understanding of erlotinib's mechanism of action, with the discovery that EGFR mutation confers higher response rate, has propelled this agent into the first line setting. Advances in molecular testing and clinical research of this agent and other agents in this class will eventually change the way we utilize EGFR TKIs in the near future. |
|---|---|
| AbstractList | The epidermal growth factor receptor (EGFR) plays an important role in the development of many cancers, including non-small cell lung cancer. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are a class of novel biologically-targeted agents widely used in the management of recurrent non-small cell lung cancer. Erlotinib, one of the EGFR TKIs, is currently FDA approved in second and third line therapy. However, recent studies showed that erlotinib is also effective as maintenance therapy after initial chemotherapy, improving disease free survival and possibly overall survival. Our current understanding of erlotinib's mechanism of action, with the discovery that EGFR mutation confers higher response rate, has propelled this agent into the first line setting. Advances in molecular testing and clinical research of this agent and other agents in this class will eventually change the way we utilize EGFR TKIs in the near future. The epidermal growth factor receptor (EGFR) plays an important role in the development of many cancers, including non-small cell lung cancer. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are a class of novel biologically-targeted agents widely used in the management of recurrent non-small cell lung cancer. Erlotinib, one of the EGFR TKIs, is currently FDA approved in second and third line therapy. However, recent studies showed that erlotinib is also effective as maintenance therapy after initial chemotherapy, improving disease free survival and possibly overall survival. Our current understanding of erlotinib's mechanism of action, with the discovery that EGFR mutation confers higher response rate, has propelled this agent into the first line setting. Advances in molecular testing and clinical research of this agent and other agents in this class will eventually change the way we utilize EGFR TKIs in the near future.The epidermal growth factor receptor (EGFR) plays an important role in the development of many cancers, including non-small cell lung cancer. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are a class of novel biologically-targeted agents widely used in the management of recurrent non-small cell lung cancer. Erlotinib, one of the EGFR TKIs, is currently FDA approved in second and third line therapy. However, recent studies showed that erlotinib is also effective as maintenance therapy after initial chemotherapy, improving disease free survival and possibly overall survival. Our current understanding of erlotinib's mechanism of action, with the discovery that EGFR mutation confers higher response rate, has propelled this agent into the first line setting. Advances in molecular testing and clinical research of this agent and other agents in this class will eventually change the way we utilize EGFR TKIs in the near future. The epidermal growth factor receptor (EGFR) plays an important role in the development of many cancers, including non-small cell lung cancer. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are a class of novel biologicallytargeted agents widely used in the management of recurrent non-small cell lung cancer. Erlotinib, one of the EGFR TKIs, is currently FDA approved in second and third line therapy. However, recent studies showed that erlotinib is also effective as maintenance therapy after initial chemotherapy, improving disease free survival and possibly overall survival. Our current understanding of erlotinib's mechanism of action, with the discovery that EGFR mutation confers higher response rate, has propelled this agent into the first line setting. Advances in molecular testing and clinical research of this agent and other agents in this class will eventually change the way we utilize EGFR TKIs in the near future. Keywords: EGFR TKI, lung cancer maintenance A video abstract by the authors of this paper is available. video-abstract5127.mov The epidermal growth factor receptor (EGFR) plays an important role in the development of many cancers, including non-small cell lung cancer. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are a class of novel biologically-targeted agents widely used in the management of recurrent non-small cell lung cancer. Erlotinib, one of the EGFR TKIs, is currently FDA approved in second and third line therapy. However, recent studies showed that erlotinib is also effective as maintenance therapy after initial chemotherapy, improving disease free survival and possibly overall survival. Our current understanding of erlotinib’s mechanism of action, with the discovery that EGFR mutation confers higher response rate, has propelled this agent into the first line setting. Advances in molecular testing and clinical research of this agent and other agents in this class will eventually change the way we utilize EGFR TKIs in the near future. The epidermal growth factor receptor (EGFR) plays an important role in the development of many cancers, including non-small cell lung cancer. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are a class of novel biologicallytargeted agents widely used in the management of recurrent non-small cell lung cancer. Erlotinib, one of the EGFR TKIs, is currently FDA approved in second and third line therapy. However, recent studies showed that erlotinib is also effective as maintenance therapy after initial chemotherapy, improving disease free survival and possibly overall survival. Our current understanding of erlotinib's mechanism of action, with the discovery that EGFR mutation confers higher response rate, has propelled this agent into the first line setting. Advances in molecular testing and clinical research of this agent and other agents in this class will eventually change the way we utilize EGFR TKIs in the near future. |
| Audience | Academic |
| Author | Benjamin C. Powers Chao H. Huang |
| AuthorAffiliation | 2 Veteran’s Administration Medical Center, Kansas City, MO 3 Hematology and Medical Oncology Fellow, University of Kansas Medical Center, Kansas City, KS 1 Associate Professor, University of Kansas Medical Center, Kansas City, KS |
| AuthorAffiliation_xml | – name: 3 Hematology and Medical Oncology Fellow, University of Kansas Medical Center, Kansas City, KS – name: 1 Associate Professor, University of Kansas Medical Center, Kansas City, KS – name: 2 Veteran’s Administration Medical Center, Kansas City, MO |
| Author_xml | – sequence: 1 givenname: Chao H. surname: Huang fullname: Huang, Chao H. email: chuang2@kumc.edu – sequence: 2 givenname: Benjamin C. surname: Powers fullname: Powers, Benjamin C. email: bpowers@kumc.edu |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22550402$$D View this record in MEDLINE/PubMed |
| BookMark | eNptU11P2zAUjaZNgzEe9gcmS5MmeCj4K3HzMglVhVWUMUF5tm4cpzVK7c5JO_Gr9hd3Q8ugHclDHN_jc3x8jz8kb33wNkk-MXoimVCng6vrk9uUcfUm2WdM5b00lfnbF-O95LBp7ik-QlCaqvfJHudpSiXl-8mfycyS4SrUK-en5CbUloSKXIHzrfXgjSUIiLB4IHdNhxguXGnjHGpyEcPvdkbOwbQhkhtr7KIbTB5iQKQll85DY8nIz1zhsNKQo-HF-Q2ZXI6aY-I8aVH5CjxM7dz6tpM9K1edZEl-BN-7RZG6N7B1TcZLVB50pfgxeVdB3djDzfcguTsfTgbfe-Pri9HgbNyDLGdtz1qwGVBZpkal1DCjyioHMMJCv7K5rESRMVkBhUKYMhMsp6mRacolZ8pkhThIRmveMsC9XkQ3h_igAzj9OBHiVENsnamtVtymRZEZKJWSAkTBc5UXsswqw3MjcuT6tuZaLIu5LQ26jVBvkW5XvJvpaVhp7FfGeYYERxuCGH4tbdPquWsMngx4G5aNZpRht6VUHfTLDvQ-LKPHo0KUkH2VScWeUVNAA85XAXVNR6rPBJV9KWjaoU5eQeFb2rkzmMLK4fzWgs8vjf5z-BQ3BJyuAQZD0kRbaeNaaF3ofLsat6i7TGvMtH7MNK443lnxRPoa9usa22CmXvr-H7hpSO0KG1toNp5gqyc7RQPahLkWtN8ZHa8JwEXXumetn5yyjKYcL5rSOOaM681Uihdw56fbFZNK_AWvTS2Q |
| CitedBy_id | crossref_primary_10_4187_respcare_02559 crossref_primary_10_1097_MD_0000000000010203 |
| Cites_doi | 10.1056/NEJMoa0800668 10.1126/science.1099314 10.1016/S0140-6736(09)61497-5 10.1093/annonc/mdq020 10.1158/1078-0432.CCR-06-0260 10.1097/JTO.0b013e3181a526b3 10.1001/jama.290.16.2149 10.1016/S0140-6736(05)67625-8 10.1200/JCO.2009.27.4365 10.1378/chest.123.1_suppl.226S 10.1016/1040-8428(94)00144-I 10.1056/NEJMoa061884 10.1200/JCO.2004.07.215 10.1200/JCO.2001.19.5.1336 10.1200/JCO.2005.05.1474 10.1158/1078-0432.CCR-05-2235 10.1016/0169-5002(95)00450-F 10.1200/JCO.2006.07.5754 10.1038/sj.bjc.6603383 10.1158/1078-0432.CCR-03-0564 10.1200/JCO.2005.02.840 10.1056/NEJMoa050753 10.1097/CAD.0b013e328349d80d 10.1016/S0140-6736(09)60569-9 10.1200/JCO.2011.39.9782 10.1056/NEJMoa0810699 10.1016/j.lungcan.2009.11.019 10.1200/JCO.2007.10.8134 10.1200/JCO.2006.05.8073 10.1016/S1470-2045(09)70364-X 10.1200/JCO.2007.15.0375 10.1111/j.1349-7006.2006.00347.x 10.1200/JCO.2004.08.001 10.1016/S1470-2045(10)70112-1 10.1097/01.JTO.0000283943.70775.a5 10.1158/0008-5472.CAN-04-2818 10.1016/S1470-2045(11)70184-X 10.1056/NEJMoa040938 10.1200/JCO.2005.04.3224 10.1056/NEJMoa0909530 10.1200/JCO.2007.13.0344 10.1093/jnci/djk195 |
| ContentType | Journal Article |
| Copyright | 2012 SAGE Publications. COPYRIGHT 2012 Sage Publications Ltd. (UK) Copyright Libertas Academica Ltd 2012 the author(s), publisher and licensee Libertas Academica Ltd. 2012 |
| Copyright_xml | – notice: 2012 SAGE Publications. – notice: COPYRIGHT 2012 Sage Publications Ltd. (UK) – notice: Copyright Libertas Academica Ltd 2012 – notice: the author(s), publisher and licensee Libertas Academica Ltd. 2012 |
| DBID | 188 AFRWT AAYXX CITATION NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AYAGU AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.4137/CMO.S5127 |
| DatabaseName | Chinese Electronic Periodical Services (CEPS) Sage Journals GOLD Open Access 2024 CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland Australia & New Zealand Database ProQuest Central Essentials - QC ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection ProQuest Central Premium ProQuest One Academic ProQuest Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest One Health & Nursing ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete ProQuest Health & Medical Research Collection Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Australia & New Zealand Database ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database PubMed MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1179-5549 |
| EndPage | 147 |
| ExternalDocumentID | oai_doaj_org_article_72e5bb6cad7743a3b2979b4d6fc29c39 PMC3306226 2743645891 A304843051 22550402 10_4137_CMO_S5127 10.4137_CMO.S5127 oai_libertasacademica_com_3081 P20160523007_201212_201605250002_201605250002_137_147 |
| Genre | Journal Article |
| GeographicLocations | United States |
| GeographicLocations_xml | – name: United States |
| GroupedDBID | --- 04C 0R~ 188 2UF 31X 3V. 53G 54M 5VS 6PF 7X7 8FI 8FJ AATBZ AAWTL ABDBF ABQXT ABUWG ABVFX ACARO ACGFS ACGZU ACIHN ACROE ACSIQ ADBBV ADOGD ADRAZ AEAQA AEWDL AEWHI AFCOW AFKRA AFKRG AFRWT AHMBA AINHJ AJUZI ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AUTPY AYAGU AYAKG BAWUL BCNDV BDDNI BENPR BMSDO BPHCQ BSEHC BVXVI CCPQU CEFSP CNMHZ DC. DIK DV7 E3Z EBD EBS EIHBH EJD ESX F5P FYUFA GROUPED_DOAJ GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION GX1 H13 HMCUK HYE IAO IHR IPNFZ ITC J8X K.F KQ8 M48 M~E O5R O5S O9- OK1 PGMZT PIMPY PQQKQ PROAC RIG RNS ROL RPM SFC SFK SFT SGV SPP TR2 TUS UKHRP UZ5 - 0R 2E 2J 2M 2N 31R 31U 31Z AACTG AAGMC AAKGS AAMXZ AAUAS ABJOC ABPTK ACJTF ACUAV ACXKE ACXMB ADACO AECGH AEDTQ AEKYL AEPTA AGWFA AMCVQ B3H B8R B8Z B94 BBAFP BBRGL BKIIM BWJAD DB DB0 DF0 DO- DV9 PQEST PQUKI PRINS Q7L Q7U Q83 SDB SGO SGR SGZ SHG SNB SPQ SPV STM AASGM ACUHS C1A PHGZM PHGZT SAUOL SCDPB SCNPE AAYXX ACHEB AFFHD CITATION NPM 7XB 8FK AGMQJ AZQEC DWQXO K9. PJZUB PKEHL PPXIY 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-a691t-eeae6a04d5c750c1c7df9aac3ea8fe94f3b614fa0ab3cd631905c45524217c6b3 |
| IEDL.DBID | PIMPY |
| ISICitedReferencesCount | 6 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000215744200014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1179-5549 |
| IngestDate | Tue Oct 14 19:06:55 EDT 2025 Tue Nov 04 01:30:52 EST 2025 Wed Oct 01 14:35:05 EDT 2025 Thu Dec 04 04:02:32 EST 2025 Sat Nov 29 13:33:45 EST 2025 Sat Nov 29 10:20:09 EST 2025 Thu Apr 03 06:58:06 EDT 2025 Sat Nov 29 08:13:44 EST 2025 Tue Nov 18 21:55:00 EST 2025 Tue Jun 17 22:37:08 EDT 2025 Thu Dec 16 16:54:48 EST 2021 Tue Oct 01 22:52:28 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | lung cancer maintenance EGFR TKI |
| Language | English |
| License | This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a691t-eeae6a04d5c750c1c7df9aac3ea8fe94f3b614fa0ab3cd631905c45524217c6b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://www.proquest.com/publiccontent/docview/1034876471?pq-origsite=%requestingapplication% |
| PMID | 22550402 |
| PQID | 1034876471 |
| PQPubID | 1096335 |
| PageCount | 11 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_72e5bb6cad7743a3b2979b4d6fc29c39 pubmedcentral_primary_oai_pubmedcentral_nih_gov_3306226 proquest_miscellaneous_1011174476 proquest_journals_1034876471 gale_infotracmisc_A304843051 gale_infotracacademiconefile_A304843051 pubmed_primary_22550402 crossref_citationtrail_10_4137_CMO_S5127 crossref_primary_10_4137_CMO_S5127 sage_journals_10_4137_CMO_S5127 libertasacademia_primary_oai_libertasacademica_com_3081 airiti_journals_P20160523007_201212_201605250002_201605250002_137_147 |
| PublicationCentury | 2000 |
| PublicationDate | 2012-01-01 |
| PublicationDateYYYYMMDD | 2012-01-01 |
| PublicationDate_xml | – month: 01 year: 2012 text: 2012-01-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | London, England |
| PublicationPlace_xml | – name: London, England – name: United States – name: London |
| PublicationTitle | Clinical Medicine Insights. Oncology |
| PublicationTitleAlternate | Clin Med Insights Oncol |
| PublicationYear | 2012 |
| Publisher | Libertas Academica SAGE Publishing SAGE Publications Sage Publications Ltd. (UK) Sage Publications Ltd |
| Publisher_xml | – name: Libertas Academica – name: SAGE Publishing – name: SAGE Publications – name: Sage Publications Ltd. (UK) – name: Sage Publications Ltd |
| References | Goldie, Coldman, Gudauskas 1982; 66 Herbst, Giaccone, Schiller 2004; 22 Reck, von Pawel, Zatloukal 2010; 21 Sheperd, Pereira, Ciuleanu 2005; 353 Maheswaran, Sequist, Nagrath 2008; 359 Kosaka, Yatabe, Endoh 2004; 64 Thatcher, Chang, Parikh 2005; 366 Salomon, Brandt, Ciardiello 1995; 19 Smith, O'Brien, Talbot 2001; 19 Lazzari, Spreafico, Bachi 2011 Socinski, Schell, Peterman 2002; 20 Lynch, Bell, Sordella 2004; 350 Zhou, Wu, Chen 2011; 12 Socinski, Morris, Masters 2003; 123 Matsuo, Ito, Yatabe 2007; 98 Mitsudomi, Morita, Yatabe 2010; 11 Mok, Wu, Thongprasert 2009; 361 Roberts, Stinchcombe, Der 2010; 28 Scagliotti, Parikh, von Pawel 2008; 26 Cappuzzo, Ciuleanu, Stelmakh 2010; 11 von Plessen, Bergman, Andresen 2006; 95 Ciuleanu, Brodowicz, Zielinski 2009; 374 Kabbinavar, Miller, Johnson 2010 Pirker, Pereira, Szczesna 2009; 373 Cohen, Williams, Sridhara 2004; 10 Lara, Redman, Kelly 2008; 26 Taguchi, Solomon, Gregorc 2007; 99 Kris, Natale, Herbst 2003; 290 Gatzemeier, Pluzanska, Szczesna 2007; 25 Pham, Kris, Riely 2006; 24 Cella, Bonomi, Lloyd 1995; 12 Park, Kim, Ahn 2007; 25 Barata, Parente, Teixeira 2007; 2 Herbst, Prager, Hermann 2005; 23 Jackman, Yeap, Lindeman 2007; 25 Perol, Chouaid, Milleron 2010 Petrelli, Borgonovo, Cabiddu 2011; 22 Maemondo, Inoue, Kobayashi 2010; 362 Sandler, Gray, Perry 2006; 355 Carbone, Seymour, Ding 2010; 5 Hamilton, Wolf, Rusk 2006; 12 Paez, Janne, Lee 2004; 304 Salmon, Chen, Chen 2009; 4 Giaccone, Gallegos Ruiz, Le Chevalier 2006; 12 Carbone, Salmon, Billheimer 2010; 69 Bezjak, Tu, Seymour 2006; 25 Giaccone, Herbst, Manegold 2004; 22 bibr22-CMO.S5127 bibr41-CMO.S5127 bibr18-CMO.S5127 bibr37-CMO.S5127 bibr5-CMO.S5127 bibr29-CMO.S5127 bibr11-CMO.S5127 bibr30-CMO.S5127 bibr14-CMO.S5127 bibr44-CMO.S5127 bibr1-CMO.S5127 bibr25-CMO.S5127 Perol M. (bibr33-CMO.S5127) 2010 bibr8-CMO.S5127 bibr21-CMO.S5127 Socinski M.A. (bibr9-CMO.S5127) 2002; 20 bibr6-CMO.S5127 bibr15-CMO.S5127 bibr28-CMO.S5127 bibr34-CMO.S5127 bibr2-CMO.S5127 bibr40-CMO.S5127 bibr7-CMO.S5127 bibr35-CMO.S5127 Lazzari C. (bibr48-CMO.S5127) 2011 Carbone D.P. (bibr47-CMO.S5127) 2010; 5 bibr43-CMO.S5127 bibr16-CMO.S5127 bibr50-CMO.S5127 bibr31-CMO.S5127 bibr12-CMO.S5127 bibr3-CMO.S5127 bibr27-CMO.S5127 bibr20-CMO.S5127 bibr38-CMO.S5127 bibr19-CMO.S5127 bibr46-CMO.S5127 Kabbinavar F.F. (bibr32-CMO.S5127) 2010 bibr17-CMO.S5127 bibr36-CMO.S5127 bibr49-CMO.S5127 bibr4-CMO.S5127 bibr42-CMO.S5127 bibr10-CMO.S5127 bibr23-CMO.S5127 bibr13-CMO.S5127 bibr45-CMO.S5127 Goldie J.H. (bibr24-CMO.S5127) 1982; 66 bibr39-CMO.S5127 bibr26-CMO.S5127 |
| References_xml | – volume: 362 start-page: 2380 year: 2010 end-page: 8 article-title: Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. publication-title: N Engl J Med. – volume: 99 start-page: 838 year: 2007 end-page: 46 article-title: Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: multicohort cross-institutional study. publication-title: J Natl Cancer Inst. – volume: 20 start-page: 1335 year: 2002 end-page: 43 article-title: Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. publication-title: J Clin Oncol. – volume: 12 start-page: 199 year: 1995 end-page: 200 article-title: Reliability and validity of the Functional Assessment of Cancer Therapy—Lung (FACT-L) quality of life instrument. publication-title: Lung Cancer. – volume: 25 start-page: 1545 year: 2007 end-page: 52 article-title: Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non-Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial. publication-title: J Clin Oncol. – volume: 123 start-page: 226S year: 2003 end-page: 43 article-title: Chemotherapeutic management of stage IV non-small cell lung cancer. publication-title: Chest. – year: 2011 article-title: Changes in Plasma Mass-Spectral Profile in Course of Treatment of Non-small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. publication-title: J Thorac Oncol. – volume: 28 start-page: 4769 year: 2010 end-page: 77 article-title: Personalized Medicine in Non-Small-Cell Lung Cancer: Is KRAS a Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor-Targeted Therapy? publication-title: J Clin Oncol. – volume: 350 start-page: 2129 year: 2004 end-page: 39 article-title: Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non- Small-Cell Lung Cancer to Gefitinib. publication-title: N Engl J Med. – volume: 353 start-page: 123 year: 2005 end-page: 32 article-title: Erlotinib in Previously Treated Non-Small-Cell Lung Cancer. publication-title: N Engl J Med. – volume: 95 start-page: 966 year: 2006 end-page: 73 article-title: Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. publication-title: Br J Cancer. – volume: 12 start-page: 735 year: 2011 end-page: 42 article-title: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomized, phase 3 study. publication-title: Lancet Oncol. – volume: 69 start-page: 337 year: 2010 end-page: 40 article-title: VeriStrat classifier for survival and time to progression in non-small-cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. publication-title: Lung Cancer. – volume: 12 start-page: 6049 year: 2006 end-page: 55 article-title: Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. publication-title: Clin Cancer Res. – issue: 28 year: 2010 article-title: Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. publication-title: J Clin Oncol. – volume: 374 start-page: 1432 issue: 9699 year: 2009 end-page: 40 article-title: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. publication-title: The Lancet. – volume: 5 year: 2010 article-title: Serum Proteomic Prediction of Outcomes in Advanced NSCLC Patients Treated with Erlotinib/Placebo in the NCIC Clinical Trials Group BR.21 Trial. publication-title: J Thorac Oncol. – volume: 25 start-page: 5233 year: 2007 end-page: 9 article-title: Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non-small-cell lung cancer. publication-title: J Clin Oncol. – volume: 26 start-page: 463 year: 2008 end-page: 7 article-title: Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. publication-title: J Clin Oncol. – volume: 25 start-page: 760 year: 2007 end-page: 6 article-title: Phase II clinical trial of chemotherapy-naïve patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. publication-title: J Clin Oncol. – volume: 64 start-page: 8919 year: 2004 end-page: 23 article-title: Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer: Biological and Clinical Implications. publication-title: Cancer Res. – volume: 11 start-page: 121 year: 2010 end-page: 8 article-title: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial. publication-title: Lancet Oncol. – volume: 66 start-page: 439 year: 1982 end-page: 49 article-title: Rationale for the use of alternating non-cross-resistant chemotherapy. publication-title: Cancer Treat Rep. – volume: 22 start-page: 785 year: 2004 end-page: 94 article-title: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2. publication-title: J Clin Oncol. – year: 2010 article-title: Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small-cell lung cancer (NSCLC). publication-title: J Clin Oncol. – volume: 23 start-page: 5892 year: 2005 end-page: 9 article-title: TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined with Carboplatin and Paclitaxel Chemotherapy in Advanced Non-Small-Cell Lung Cancer. publication-title: J Clin Oncol. – volume: 11 start-page: 521 year: 2010 end-page: 9 article-title: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomized, placebo-controlled phase 3 study. publication-title: Lancet Oncol. – volume: 4 start-page: 689 year: 2009 end-page: 96 article-title: Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen. publication-title: J Thorac Oncol. – volume: 22 start-page: 1010 year: 2011 end-page: 9 article-title: Erlotinib as maintenance therapy in patients with advanced non-small cell lung cancer: a pooled analysis of three randomized trials. publication-title: Anticancer Drugs. – volume: 26 start-page: 3543 year: 2008 end-page: 51 article-title: Phase III study comparing cisplatin plus gemcitabine with cispltin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. publication-title: J Clin Oncol. – volume: 19 start-page: 1336 year: 2001 end-page: 43 article-title: Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. publication-title: J Clin Oncol. – volume: 304 start-page: 1497 year: 2004 end-page: 500 article-title: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. publication-title: Science. – volume: 22 start-page: 777 year: 2004 end-page: 84 article-title: Gefitinib in Combination with Gemcitabine and Cisplatin in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial—INTACT 1. publication-title: J Clin Oncol. – volume: 25 start-page: 3831 year: 2006 end-page: 7 article-title: Symptom improvement in lung cancer patients treated with erlotinib: Quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group study BR.21. publication-title: J Clin Oncol. – volume: 98 start-page: 96 year: 2007 end-page: 101 article-title: Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese. publication-title: Cancer Science. – volume: 24 start-page: 1700 year: 2006 end-page: 4 article-title: Use of Cigarette-Smoking History to Estimate the Likelihood of Mutations in Epidermal Growth Factor Receptor Gene Exons 19 and 21 in Lung Adenocarcinomas. publication-title: J Clin Oncol. – volume: 366 start-page: 1527 year: 2005 end-page: 37 article-title: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). publication-title: Lancet. – volume: 290 start-page: 2149 year: 2003 end-page: 58 article-title: Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer. publication-title: JAMA. – volume: 359 start-page: 366 year: 2008 end-page: 77 article-title: Detection of mutations in EGFR in circulating lung-cancer cells. publication-title: N Engl J Med. – volume: 361 start-page: 947 year: 2009 end-page: 57 article-title: Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. publication-title: N Engl J Med. – volume: 19 start-page: 183 year: 1995 end-page: 232 article-title: Epidermal growth factor-related peptides and their receptors in human malignancies. publication-title: Crit Rev Oncol Hematol. – volume: 373 start-page: 1525 year: 2009 end-page: 31 article-title: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomized phase III trial. publication-title: Lancet. – volume: 10 start-page: 1212 year: 2004 end-page: 8 article-title: Report from the FDA: United States Food and Drug Administration Drug Approval Summary: Gefitinib (ZD1839; Iressa) Tablets. publication-title: Clin Cancer Res. – volume: 21 start-page: 1804 year: 2010 end-page: 9 article-title: Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for non-squamous non-small-cell lung cancer: results from a randomized phase III trial (AVAIL). publication-title: Ann Oncol. – volume: 12 start-page: 2166 year: 2006 end-page: 71 article-title: Effects of Smoking on the Pharmacokinetics of Erlotinib. publication-title: Clin Cancer Res. – volume: 355 start-page: 2542 year: 2006 end-page: 50 article-title: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. publication-title: N Engl J Med. – volume: 2 start-page: S666 year: 2007 article-title: Optimal duration of chemotherapy in non-small-cell lung cancer: multicenter, randomized, prospective clinical trial comparing 4 vs. 6 cycles of carboplatin and gemcitabine. publication-title: J Thorac Oncol. – volume: 66 start-page: 439 year: 1982 ident: bibr24-CMO.S5127 publication-title: Cancer Treat Rep. – ident: bibr49-CMO.S5127 doi: 10.1056/NEJMoa0800668 – ident: bibr2-CMO.S5127 – ident: bibr18-CMO.S5127 doi: 10.1126/science.1099314 – ident: bibr29-CMO.S5127 doi: 10.1016/S0140-6736(09)61497-5 – year: 2011 ident: bibr48-CMO.S5127 publication-title: J Thorac Oncol. – ident: bibr5-CMO.S5127 doi: 10.1093/annonc/mdq020 – ident: bibr35-CMO.S5127 doi: 10.1158/1078-0432.CCR-06-0260 – ident: bibr45-CMO.S5127 doi: 10.1097/JTO.0b013e3181a526b3 – ident: bibr13-CMO.S5127 doi: 10.1001/jama.290.16.2149 – ident: bibr14-CMO.S5127 doi: 10.1016/S0140-6736(05)67625-8 – ident: bibr50-CMO.S5127 doi: 10.1200/JCO.2009.27.4365 – ident: bibr22-CMO.S5127 doi: 10.1378/chest.123.1_suppl.226S – ident: bibr19-CMO.S5127 doi: 10.1016/1040-8428(94)00144-I – volume: 5 year: 2010 ident: bibr47-CMO.S5127 publication-title: J Thorac Oncol. – ident: bibr3-CMO.S5127 doi: 10.1056/NEJMoa061884 – ident: bibr26-CMO.S5127 doi: 10.1200/JCO.2004.07.215 – ident: bibr11-CMO.S5127 doi: 10.1200/JCO.2001.19.5.1336 – ident: bibr28-CMO.S5127 doi: 10.1200/JCO.2005.05.1474 – ident: bibr20-CMO.S5127 doi: 10.1158/1078-0432.CCR-05-2235 – ident: bibr31-CMO.S5127 doi: 10.1016/0169-5002(95)00450-F – ident: bibr36-CMO.S5127 doi: 10.1200/JCO.2006.07.5754 – ident: bibr12-CMO.S5127 doi: 10.1038/sj.bjc.6603383 – ident: bibr15-CMO.S5127 doi: 10.1158/1078-0432.CCR-03-0564 – ident: bibr27-CMO.S5127 doi: 10.1200/JCO.2005.02.840 – ident: bibr16-CMO.S5127 doi: 10.1056/NEJMoa050753 – ident: bibr21-CMO.S5127 – ident: bibr34-CMO.S5127 doi: 10.1097/CAD.0b013e328349d80d – ident: bibr4-CMO.S5127 doi: 10.1016/S0140-6736(09)60569-9 – ident: bibr1-CMO.S5127 – issue: 28 year: 2010 ident: bibr33-CMO.S5127 publication-title: J Clin Oncol. doi: 10.1200/JCO.2011.39.9782 – ident: bibr37-CMO.S5127 doi: 10.1056/NEJMoa0810699 – ident: bibr46-CMO.S5127 doi: 10.1016/j.lungcan.2009.11.019 – ident: bibr8-CMO.S5127 doi: 10.1200/JCO.2007.10.8134 – ident: bibr23-CMO.S5127 doi: 10.1200/JCO.2006.05.8073 – ident: bibr42-CMO.S5127 doi: 10.1016/S1470-2045(09)70364-X – ident: bibr6-CMO.S5127 doi: 10.1200/JCO.2007.15.0375 – ident: bibr41-CMO.S5127 doi: 10.1111/j.1349-7006.2006.00347.x – ident: bibr25-CMO.S5127 doi: 10.1200/JCO.2004.08.001 – ident: bibr30-CMO.S5127 doi: 10.1016/S1470-2045(10)70112-1 – ident: bibr10-CMO.S5127 doi: 10.1097/01.JTO.0000283943.70775.a5 – ident: bibr40-CMO.S5127 doi: 10.1158/0008-5472.CAN-04-2818 – ident: bibr39-CMO.S5127 doi: 10.1016/S1470-2045(11)70184-X – volume: 20 start-page: 1335 year: 2002 ident: bibr9-CMO.S5127 publication-title: J Clin Oncol. – year: 2010 ident: bibr32-CMO.S5127 publication-title: J Clin Oncol. – ident: bibr17-CMO.S5127 doi: 10.1056/NEJMoa040938 – ident: bibr38-CMO.S5127 doi: 10.1200/JCO.2005.04.3224 – ident: bibr43-CMO.S5127 doi: 10.1056/NEJMoa0909530 – ident: bibr7-CMO.S5127 doi: 10.1200/JCO.2007.13.0344 – ident: bibr44-CMO.S5127 doi: 10.1093/jnci/djk195 |
| SSID | ssj0000330057 |
| Score | 1.8681973 |
| SecondaryResourceType | review_article |
| Snippet | The epidermal growth factor receptor (EGFR) plays an important role in the development of many cancers, including non-small cell lung cancer. Epidermal growth... A video abstract by the authors of this paper is available. video-abstract5127.mov The epidermal growth factor receptor (EGFR) plays an important role in the... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref sage libertasacademia airiti |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 137 |
| SubjectTerms | Antimitotic agents Antineoplastic agents Drug therapy Health aspects Lung cancer, Non-small cell Review |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3fb9MwELbQNCFeYPwOG2AQEuMhrI2TeHksVTumrWXaCtqb5TiOGilKp7ZD4q_iX-Q7J-uaMokX3trYsh37u_OdffmOsQ94mIdxbvwstHBQRCZ8HSQQPKAjI3KYwB24_TiV4_Hh5WVytpbqi2LCanrgeuIOZGCjNI2NzmCoCC3SIJFJGmZoP0iMcJ_uwepZc6acDhZEwy5rKiHoaXnQH337fBG57DHbuiDCoNZO5Aj7V2r5UU1tqxe6DlLXd9mff4dRrsWCue1puMMeNnYl79Xv85jds9UTdn_U3Jw_Zb-BBz6ALqIDBH4-Ky2f5XykiS6CODcsn9T8AtwFEfABZY6F0i75ERz15ZQPXWIeDjPTXtGPyS-8FZrmJ0WFnZAfV9MiLSh3D98fHA3P-eTkePGJFxWHiclvo2yo214TeMDHs8q_QCel37dlyU-heXifiubP2PfhYNL_6jfJGnwdJ92lb622se6EWWRghJiukVmeaG2E1Ye5TcJcpLAEct3RqTBZDMnvRCaMIrqSliZOxXO2Vc0q-5LxbixhlmR0BRmHMoxSmKQSpk0SBSl5dB4b1CuoGnlbqLOAmPLohLsjVUA8dYFqHlHGh40_wANcHumx_RsAKNMwolNijlLBMyLQKIBGOdB47P2q6lVNA3JXpS-EolUFYu52D4Bn1eBZ_QvPHvtIGFSkXzAY0yDQYGqIqUv1BHQu8bR1PbbXqgm9YFrFchPFrZFtFBqtoOKUgImIhm_AfjvD3Y6Ab4v1QPG7VTH1SVF6lZ1dUx3snDIMZeyxF7VsrLrEvhFhwwgwrJbUtMbULqmKqeM7hyzH8BI89pbka31IGwvw6n8swC57QACqj9n22NZyfm1fs23zc1ks5m-cmvkDtHF9lg priority: 102 providerName: Directory of Open Access Journals |
| Title | The Evolving Role of Maintenance Therapy Using Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) in the Management of Advanced Non-Small-Cell Lung Cancer |
| URI | https://www.airitilibrary.com/Article/Detail/P20160523007-201212-201605250002-201605250002-137-147 http://insights.sagepub.com/the-evolving-role-of-maintenance-therapy-using-epidermal-growth-factor-article-a3081 https://journals.sagepub.com/doi/full/10.4137/CMO.S5127 https://www.ncbi.nlm.nih.gov/pubmed/22550402 https://www.proquest.com/docview/1034876471 https://www.proquest.com/docview/1011174476 https://pubmed.ncbi.nlm.nih.gov/PMC3306226 https://doaj.org/article/72e5bb6cad7743a3b2979b4d6fc29c39 |
| Volume | 2012 |
| WOSCitedRecordID | wos000215744200014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1179-5549 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000330057 issn: 1179-5549 databaseCode: DOA dateStart: 20070101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1179-5549 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000330057 issn: 1179-5549 databaseCode: M~E dateStart: 20100101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Australia & New Zealand Database customDbUrl: eissn: 1179-5549 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000330057 issn: 1179-5549 databaseCode: AYAGU dateStart: 20100101 isFulltext: true titleUrlDefault: https://search.proquest.com/anz providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1179-5549 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000330057 issn: 1179-5549 databaseCode: 7X7 dateStart: 20100101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1179-5549 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000330057 issn: 1179-5549 databaseCode: BENPR dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1179-5549 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000330057 issn: 1179-5549 databaseCode: PIMPY dateStart: 20070101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3fb9MwELZYOyFeGL8JjGIQEuMhrI2TuHlCXdWOamuptoLKk-U4Do0UJaXtQPxV_IvcJW67lIknXqo2tmon_e67s339jpA3cDF2_VjZkathgcIiZksnAMMDdEQoDuMUG25fzvlo1J5Og7H5e_TSpFWuObEg6lLtGfO2gYSPo1zhjjnYOoNI2wdm_TD_bmMNKTxrNQU19kgdhbfaNVIfD4bjr5s9lyZDcXZeCgwBe_Pj7vDT-0uvqCmzLxOUEar4p0LGf0PWB6XgrVzKMnVd3hSV_p1ceS1DrHBa_YP_e7v3yF0TvNJOibb75JbOHpDbQ3M8_5D8BtDRHhAe7lLQizzVNI_pUKImBQp7aDopRQxokalAe1ieFjxDSk8X-c_VjPaL6j8UYlk9xzeTX_CQ4KvpWZKBu6WDbJaECRYIoke90_4FnZwNlu9oklGIY-k2lQeH7ZjsBjrKM_sSBkntrk5Teg70RrvYtHhEPvd7k-5H21SEsKUftFa21lL7sulGnoJIR7UUj-JASsW0bMc6cGMWQrgRy6YMmYp8oJemp1zPw3NvrvyQPSa1LM_0U0JbPofYJ8JzTniurhdC3Mshfgo8J8Rlo0V6JSCEMeqlGDsox4fb6E0uHBTDc4S5hGUldj4AvGBdxS1ytMaTUEZ2Hat_pAKWX4hBARgUBQYt8nrTdV5qjdzU6QRBuemA8uDFhXzxTRi2EdzRXhj6AFOI7plkoRPwIHQjMEonUAxu7i1CWiCJwWSUATTATqMcmOgwIHYUg2tZ5LDSE8hHVZr5rlFUZrbTqKQAkAsGcSh88Rr42ye8xblFXm2acUxMBcx0foV9wD1z1-W-RZ6UprYZEpyTB17JgWlVjLAyp2pLlswKUXWgBh-WIhZ5ieZ6fUo7P8Czf0_8ObmD0Ch36Q5JbbW40i_IvvqxSpaLBtnjU168thukftIbjS8axTZQw3DVH1N3nG0 |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEF6VUgEXyhtDoQsCtRwMiV9bHxAqIWmjPKjagHpb1us1jRTZJUmp-qfgL_KN7aR1qLj1wC3xrryb3ZlvZnYn3zD2Cg8TL0i0HXsGAYobu7ZyQigepCMmchgnP3D72hX9_tbhYbi3xH7N_gtDaZUzTMyBOs40nZFDu1341gGw9MPxD5uqRtHt6qyERiEWHXN2ipBt8r79Cfv72nFazUFj1y6rCtgqCOtT2xhlAlXzYl_DWuq6FnESKqVdo7YSE3qJG8FkJaqmIlfHAUS05mvP9-nuVOggcvHea-w6cFxQCpk4FPMznZpL5O-iIDCCdRDvGr3Pbw_8vGbNihoSTVHF_uVlAubGYLUg1FUTVaTGq8u83r-TNy9koOVGsbX6vy3nHXa7dL_5dqEvd9mSSe-xG70yweA--w214U1ANp2z8P1sZHiW8J4iVg2iJjF8UNAw8DzXgjepwC5s24jvjLPT6RFv5fWLOLxxc0wfBmfYBryad4YpHAbeTo-G0ZBKHPHN5k5rnw867ckbPkw5PHF-noxEw26X-Rm8n6X2AQYZ2Q0zGvEuAJo3qGn8gH25kuV6yJbTLDWPGa8HAt5bTDe12EfPj-C5C3iAoe9EFPharFmInCxhaSL3HCIUpIuAmpAO0fk5snxEhTEWvkCAERkKi23OJFbqkjie6peMJAJIknIJKZe5lFvs5bzrccGWclmnjyT28w5EcJ4_yMbfZYmXUjjGj6IAioD4xFVuBHULIy8GrDihdvHjNkhpJMEwJqNLldFYGiI0k9suTBPR2dUttlbpCfjUlWaxqHaVmS00aiWhRtKFJ40Xz1TrfIXP9cpiL-bNNCYlM6YmO6E-cDCE54nAYo8KZZ4PCfPqw646mFZFzStzqrakw6OcFh7gEyCYstg6AcLFKS1swJN_T3yd3dwd9Lqy2-53nrJbJCbFmeMaW56OT8wztqJ_ToeT8fMc_Tj7dtX48AfgDOpC |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Evolving+Role+of+Maintenance+Therapy+Using+Epidermal+Growth+Factor+Receptor+Tyrosine+Kinase+Inhibitors+%28EGFR+TKIs%29+in+the+Management+of+Advanced+Non-Small-Cell+Lung+Cancer&rft.jtitle=Clinical+Medicine+Insights.+Oncology&rft.au=Huang%2C+Chao+H.&rft.au=Powers%2C+Benjamin+C.&rft.date=2012-01-01&rft.pub=Libertas+Academica&rft.eissn=1179-5549&rft.volume=6&rft.spage=137&rft.epage=147&rft_id=info:doi/10.4137%2FCMO.S5127&rft_id=info%3Apmid%2F22550402&rft.externalDocID=PMC3306226 |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fwww.airitilibrary.com%2Fjnltitledo%2FP20160523007-c.jpg |